Company intelligence / Profile preview

XCancer

Omaha, Nebraska, United States

Ownership: Private
Development stage: Other

Overview

XCancer (formerly Urology Cancer Center) is a leading independent urologic oncology clinic and research site in Omaha, Nebraska. It is recognized for pioneering first-in-human, first-in-U.S., and first-in-world treatments in prostate and other urologic cancers. The center offers access to advanced radiopharmaceuticals such as Lutetium-based therapies for PSMA-positive metastatic prostate cancer. Patients are referred nationally—including from major academic centers—for innovative care options not widely available elsewhere. Over 400 patients per month receive care at the facility[4].

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalSmall moleculeBiologic
Industry: Academic Hospital/University/Research

Beyond the preview

Go deeper on XCancer.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XCancer.

Explore the full profile